221 related articles for article (PubMed ID: 15380483)
1. Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis.
Kaminski HJ; Li Z; Richmonds C; Lin F; Medof ME
Exp Neurol; 2004 Oct; 189(2):333-42. PubMed ID: 15380483
[TBL] [Abstract][Full Text] [Related]
2. Deficiency of decay accelerating factor and CD59 leads to crisis in experimental myasthenia.
Kaminski HJ; Kusner LL; Richmonds C; Medof ME; Lin F
Exp Neurol; 2006 Dec; 202(2):287-93. PubMed ID: 16859686
[TBL] [Abstract][Full Text] [Related]
3. Complement regulator CD59 deficiency fails to augment susceptibility to actively induced experimental autoimmune myasthenia gravis.
Tüzün E; Saini SS; Morgan BP; Christadoss P
J Neuroimmunol; 2006 Dec; 181(1-2):29-33. PubMed ID: 17056125
[TBL] [Abstract][Full Text] [Related]
4. Ocular myasthenia gravis induced by human acetylcholine receptor ϵ subunit immunization in HLA DR3 transgenic mice.
Wu X; Tuzun E; Saini SS; Wang J; Li J; Aguilera-Aguirre L; Huda R; Christadoss P
Immunol Lett; 2015 Dec; 168(2):306-12. PubMed ID: 26493475
[TBL] [Abstract][Full Text] [Related]
5. Increased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravis.
Losen M; Stassen MH; Martínez-Martínez P; Machiels BM; Duimel H; Frederik P; Veldman H; Wokke JH; Spaans F; Vincent A; De Baets MH
Brain; 2005 Oct; 128(Pt 10):2327-37. PubMed ID: 16150851
[TBL] [Abstract][Full Text] [Related]
6. Extraocular muscle susceptibility to myasthenia gravis: unique immunological environment?
Soltys J; Gong B; Kaminski HJ; Zhou Y; Kusner LL
Ann N Y Acad Sci; 2008; 1132():220-4. PubMed ID: 18567871
[TBL] [Abstract][Full Text] [Related]
7. Oral administration of a dual analog of two myasthenogenic T cell epitopes down-regulates experimental autoimmune myasthenia gravis in mice.
Paas-Rozner M; Dayan M; Paas Y; Changeux JP; Wirguin I; Sela M; Mozes E
Proc Natl Acad Sci U S A; 2000 Feb; 97(5):2168-73. PubMed ID: 10681457
[TBL] [Abstract][Full Text] [Related]
8. A new mouse model of autoimmune ocular myasthenia gravis.
Yang H; Wu B; Tüzün E; Saini SS; Li J; Allman W; Higgs S; Xiao TL; Christadoss P
Invest Ophthalmol Vis Sci; 2007 Nov; 48(11):5101-11. PubMed ID: 17962462
[TBL] [Abstract][Full Text] [Related]
9. Ocular and generalized myasthenia gravis induced by human acetylcholine receptor γ subunit immunization.
Wu X; Tuzun E; Li J; Xiao T; Saini SS; Qi H; Allman W; Christadoss P
Muscle Nerve; 2012 Feb; 45(2):209-16. PubMed ID: 22246876
[TBL] [Abstract][Full Text] [Related]
10. Acetylcholine receptor-induced experimental myasthenia gravis: what have we learned from animal models after three decades?
Baggi F; Antozzi C; Toscani C; Cordiglieri C
Arch Immunol Ther Exp (Warsz); 2012 Feb; 60(1):19-30. PubMed ID: 22159475
[TBL] [Abstract][Full Text] [Related]
11. Genetic evidence for the involvement of Fcgamma receptor III in experimental autoimmune myasthenia gravis pathogenesis.
Tüzün E; Saini SS; Yang H; Alagappan D; Higgs S; Christadoss P
J Neuroimmunol; 2006 May; 174(1-2):157-67. PubMed ID: 16527362
[TBL] [Abstract][Full Text] [Related]
12. Pathophysiology of myasthenia gravis.
Hughes BW; Moro De Casillas ML; Kaminski HJ
Semin Neurol; 2004 Mar; 24(1):21-30. PubMed ID: 15229789
[TBL] [Abstract][Full Text] [Related]
13. Acetylcholine receptor expression in human extraocular muscles and their susceptibility to myasthenia gravis.
MacLennan C; Beeson D; Buijs AM; Vincent A; Newsom-Davis J
Ann Neurol; 1997 Apr; 41(4):423-31. PubMed ID: 9124798
[TBL] [Abstract][Full Text] [Related]
14. The role of complement in experimental autoimmune myasthenia gravis.
Kusner LL; Kaminski HJ
Ann N Y Acad Sci; 2012 Dec; 1274(1):127-32. PubMed ID: 23252907
[TBL] [Abstract][Full Text] [Related]
15. Complement activation cascade and its regulation: relevance for the response of solid tumors to photodynamic therapy.
Korbelik M; Cecic I
J Photochem Photobiol B; 2008 Oct; 93(1):53-9. PubMed ID: 18715798
[TBL] [Abstract][Full Text] [Related]
16. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.
Cole RN; Reddel SW; Gervásio OL; Phillips WD
Ann Neurol; 2008 Jun; 63(6):782-9. PubMed ID: 18384168
[TBL] [Abstract][Full Text] [Related]
17. Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection.
Lin F; Kaminski HJ; Conti-Fine BM; Wang W; Richmonds C; Medof ME
J Clin Invest; 2002 Nov; 110(9):1269-74. PubMed ID: 12417565
[TBL] [Abstract][Full Text] [Related]
18. Experimental autoimmune myasthenia gravis in the mouse.
Wu B; Goluszko E; Huda R; Tüzün E; Christadoss P
Curr Protoc Immunol; 2011 Nov; Chapter 15():Unit 15.23. PubMed ID: 22048803
[TBL] [Abstract][Full Text] [Related]
19. Experimental autoimmune myasthenia gravis in the mouse.
Wu B; Goluszko E; Huda R; Tüzün E; Christadoss P
Curr Protoc Immunol; 2013; Chapter 15():Unit 15.8.. PubMed ID: 23392639
[TBL] [Abstract][Full Text] [Related]
20. Increased gene expression of acetylcholine receptor and myogenic factors in passively transferred experimental autoimmune myasthenia gravis.
Asher O; Kues WA; Witzemann V; Tzartos SJ; Fuchs S; Souroujon MC
J Immunol; 1993 Dec; 151(11):6442-50. PubMed ID: 8245477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
